FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1571437601> ?p ?o ?g. }

• W1571437601 abstract "Cystic fibrosis is an inherited condition resulting in thickened, sticky respiratory secretions. Respiratory failure, due to recurrent pulmonary infection and inflammation, is the most common cause of mortality. Muco-active therapies (e.g. dornase alfa and nebulized hypertonic saline) may decrease sputum viscosity, increase airway clearance of sputum, reduce infection and inflammation and improve lung function. Thiol derivatives, either oral or nebulized, have shown benefit in other respiratory diseases. Their mode of action is likely to differ according to the route of administration. There are several thiol derivatives, and it is unclear which of these may be beneficial in cystic fibrosis.To evaluate the efficacy and safety of nebulized and oral thiol derivatives in people with cystic fibrosis.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, comprising references identified from comprehensive electronic database searches, hand searches of relevant journals, abstract books and conference proceedings.Most recent search: 13 June 2013.We also conducted a PubMed search on 26 February 2013 for relevant published articles.Randomized and quasi-randomized controlled trials comparing nebulized or oral thiol derivatives to placebo or another thiol derivative in people with cystic fibrosis.The authors independently assessed trials for inclusion, analysed risk of bias and extracted data.Searches identified 23 trials; nine trials (255 participants) are included, of these seven trials are more than 10 years old. Three trials of nebulized thiol derivatives were identified (one compared 20% N-acetylcysteine to 2% N-acetylcysteine; another compared sodium-2-mercaptoethane sulphonate to 7% hypertonic saline; and another compared glutathione to 4% hypertonic saline). Although generally well-tolerated with no significant adverse effects, there was no evidence of significant clinical benefit in our primary outcomes in participants receiving these treatments.Six trials of oral thiol derivatives were identified. Three trials compared N-acetylcysteine to placebo; one compared N-acetylcysteine, ambroxol and placebo; one compared carbocysteine to ambroxol; and one compared low and high-dose N-acetylcysteine. Oral thiol derivatives were generally well-tolerated with no significant adverse effects, however there was no evidence of significant clinical benefit in our primary outcomes in participants receiving these treatments.We found no evidence to recommend the use of either nebulized or oral thiol derivatives in people with cystic fibrosis. There are very few good quality trials investigating the effect of these medications in cystic fibrosis, and further research is required to investigate the potential role of these medications in improving the outcomes of people with cystic fibrosis." @default.
• W1571437601 created "2016-06-24" @default.
• W1571437601 creator A5003812454 @default.
• W1571437601 creator A5017024281 @default.
• W1571437601 creator A5059623032 @default.
• W1571437601 creator A5068917441 @default.
• W1571437601 creator A5071974407 @default.
• W1571437601 date "2013-07-12" @default.
• W1571437601 modified "2023-09-27" @default.
• W1571437601 title "Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis" @default.
• W1571437601 cites W1494704219 @default.
• W1571437601 cites W1536412649 @default.
• W1571437601 cites W177063975 @default.
• W1571437601 cites W1906831711 @default.
• W1571437601 cites W1967713626 @default.
• W1571437601 cites W1973103000 @default.
• W1571437601 cites W1994502544 @default.
• W1571437601 cites W2002548503 @default.
• W1571437601 cites W2003493994 @default.
• W1571437601 cites W2016070827 @default.
• W1571437601 cites W2033451677 @default.
• W1571437601 cites W2040779743 @default.
• W1571437601 cites W2040812975 @default.
• W1571437601 cites W2049498202 @default.
• W1571437601 cites W2055473332 @default.
• W1571437601 cites W2058432179 @default.
• W1571437601 cites W2074706139 @default.
• W1571437601 cites W2096484542 @default.
• W1571437601 cites W2098324134 @default.
• W1571437601 cites W2099647732 @default.
• W1571437601 cites W2101012923 @default.
• W1571437601 cites W2102721284 @default.
• W1571437601 cites W2103043501 @default.
• W1571437601 cites W2111467322 @default.
• W1571437601 cites W2125435699 @default.
• W1571437601 cites W2130235475 @default.
• W1571437601 cites W2130723231 @default.
• W1571437601 cites W2159296411 @default.
• W1571437601 cites W2161919334 @default.
• W1571437601 cites W2164402604 @default.
• W1571437601 cites W2164877517 @default.
• W1571437601 cites W2166059037 @default.
• W1571437601 cites W2333398204 @default.
• W1571437601 cites W2413941012 @default.
• W1571437601 cites W4232133563 @default.
• W1571437601 cites W4239274289 @default.
• W1571437601 cites W4249200669 @default.
• W1571437601 doi "https://doi.org/10.1002/14651858.cd007168.pub3" @default.
• W1571437601 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8078644" @default.
• W1571437601 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23852992" @default.
• W1571437601 hasPublicationYear "2013" @default.
• W1571437601 type Work @default.
• W1571437601 sameAs 1571437601 @default.
• W1571437601 citedByCount "51" @default.
• W1571437601 countsByYear W15714376012012 @default.
• W1571437601 countsByYear W15714376012014 @default.
• W1571437601 countsByYear W15714376012015 @default.
• W1571437601 countsByYear W15714376012016 @default.
• W1571437601 countsByYear W15714376012017 @default.
• W1571437601 countsByYear W15714376012018 @default.
• W1571437601 countsByYear W15714376012019 @default.
• W1571437601 countsByYear W15714376012020 @default.
• W1571437601 countsByYear W15714376012021 @default.
• W1571437601 countsByYear W15714376012022 @default.
• W1571437601 crossrefType "journal-article" @default.
• W1571437601 hasAuthorship W1571437601A5003812454 @default.
• W1571437601 hasAuthorship W1571437601A5017024281 @default.
• W1571437601 hasAuthorship W1571437601A5059623032 @default.
• W1571437601 hasAuthorship W1571437601A5068917441 @default.
• W1571437601 hasAuthorship W1571437601A5071974407 @default.
• W1571437601 hasBestOaLocation W15714376012 @default.
• W1571437601 hasConcept C126322002 @default.
• W1571437601 hasConcept C142724271 @default.
• W1571437601 hasConcept C168563851 @default.
• W1571437601 hasConcept C185592680 @default.
• W1571437601 hasConcept C204787440 @default.
• W1571437601 hasConcept C27081682 @default.
• W1571437601 hasConcept C2776301714 @default.
• W1571437601 hasConcept C2776938444 @default.
• W1571437601 hasConcept C2777847592 @default.
• W1571437601 hasConcept C2778004101 @default.
• W1571437601 hasConcept C2781069245 @default.
• W1571437601 hasConcept C3017567848 @default.
• W1571437601 hasConcept C535046627 @default.
• W1571437601 hasConcept C55493867 @default.
• W1571437601 hasConcept C71924100 @default.
• W1571437601 hasConceptScore W1571437601C126322002 @default.
• W1571437601 hasConceptScore W1571437601C142724271 @default.
• W1571437601 hasConceptScore W1571437601C168563851 @default.
• W1571437601 hasConceptScore W1571437601C185592680 @default.
• W1571437601 hasConceptScore W1571437601C204787440 @default.
• W1571437601 hasConceptScore W1571437601C27081682 @default.
• W1571437601 hasConceptScore W1571437601C2776301714 @default.
• W1571437601 hasConceptScore W1571437601C2776938444 @default.
• W1571437601 hasConceptScore W1571437601C2777847592 @default.
• W1571437601 hasConceptScore W1571437601C2778004101 @default.
• W1571437601 hasConceptScore W1571437601C2781069245 @default.
• W1571437601 hasConceptScore W1571437601C3017567848 @default.
• W1571437601 hasConceptScore W1571437601C535046627 @default.
• W1571437601 hasConceptScore W1571437601C55493867 @default.

• next